The cost of Ozempic has more than doubled due to unprecedented global demand for the medication. We've absorbed these increasing costs so far, but in order to continue providing your treatment we've had to make this change.

Our team has worked around the clock to secure enough medication in light of the shortages. At the present time, the cost of the medication alone exceeds what we charge for the entire programme.

We're doing everything in our power to manage this situation responsibly. Our priority is for you to continue on a successful weight loss journey without interruptions. Increasing the price allows us to continue buying the medication for your treatment.

We are proactively managing our resources and working diligently with our suppliers to avoid any disruption in the availability of the medication. Our priority is to ensure the continued treatment of our patients, and we are confident in our ability to source the necessary stock to maintain the high-quality care you deserve.

We do not anticipate further changes to price at this time. Our goal is to revisit pricing as soon as the situation with the shortage improves. We will continue to communicate any changes from our suppliers as they come through.

The duration of the medication shortage is difficult to predict, as it depends on patient demand and manufacturer supply, as well as market and prescribing regulations. We are actively monitoring the situation and working closely with our suppliers to secure medication, and will keep you informed of any changes to Juniper based on the shortage.

Yes, we are committed to keeping our patients informed about any changes in the medication shortage situation.

As soon as it becomes feasible to revert the changes in light of the evolving shortage, our goal is to do so and return to our structure.

We will promptly communicate any updates or improvements to ensure you stay well-informed throughout this process.

Yes, we understand the importance of keeping you informed about the medication shortage and its impact on the programme. Our team will be providing regular updates and maintaining open lines of communication to ensure you stay informed about any changes and developments. We are committed to transparency and keeping you up to date as we navigate this situation together.

The success of GLP-1 agonists in the treatment of obesity has prompted high demand for the medication across the world. This places pressure on manufacturers to create higher volumes of medication, and creates sourcing limitations for suppliers. For Juniper, we have secured enough medication for our patients, but at an increased cost price, and while we have been able to absorb the cost, the most recent shortage forces us to pass this on to patients.

When we began to experience rising costs in May 2023, we worked with our Medical Director in Australia, our clinical team in the UK, and suppliers in the UK and across Europe to develop a solution that would allow patients to continue accessing their treatment with support from health coaches and pharmacists.

In order to achieve this, we were forced to increase the price to match the rise of the medication cost (which has increased by over 200% since we launched Juniper only a year ago). While other providers have been forced to close their doors and turn away patients, we have strived to continue to service existing patients to the best of our ability by increasing the cost of the programme and pausing new patients from joining Juniper.

This decision did not come lightly, and we are working with suppliers and our clinical team to communicate any further changes that arise from this evolving supply issue. We welcome all feedback and suggestions, and appreciate your patience.

We are exploring additional medication offerings to expand treatments and diversify medication supply, to mitigate shortage issues that may arise in future. We are working with manufacturers, medical experts, and suppliers to meet this, but in the meantime, our core medication offering remains the same. Whilst there are other medications on the market, we believe semaglutide to be one of the most clinically effective treatments for treating obesity. We aim to continue to provide best-in-market service through evidence-backed treatments alongside our health coaching and app offering.

We will readjust the price when the medication costs reduce, but we cannot promise when this will occur.

We're prioritising keeping the cost as low as possible for existing patients. If we re-open the programme to new patients, their subscription price will be higher than £225 to help subsidise the increasing costs.

Each 0.25mg Ozempic pen is loaded by the manufacturer with up to 2 extra doses. This is to ensure that each dose is correctly delivered in full at all times and to account for any errors or maladministration.

As per manufacturing instructions, we cannot clinically recommend using this.

Our team has worked around the clock to secure enough medication in light of the shortages. At the present time, the cost of the medication alone exceeds what we charge you for the entire programme.

We're doing everything in our power to manage this situation responsibly.

Unfortunately, due to the sharp increase in Ozempic costs, we can no longer offer dosages that require more than one pen at the regular price.

Our team has worked around the clock to secure enough medication in light of the shortages. At the present time, the cost of the medication alone exceeds what we charge you for the entire programme.

All patients will continue on a 7 day dosing schedule.

To ensure we achieve clinical efficacy during a shortage, we consulted the advice issued by the Department of Health & Social Care and the NHS Specialist Pharmacy Service, who suggest that it is appropriate to change the dose schedule due to the severe shortage of semaglutide. Semaglutide (Ozempic) is a long-acting medication, meaning that the steady-state of active medication remains in the circulation for up to 5 weeks after the last injection. Once a patient has been using the medication for 4-5 weeks, the medication will remain at an effective dose level beyond 7 days after the last injection. Due to the way that the medication is metabolised, at 10 days, the dose in circulation will remain at a slightly lower, but still very effective level. This will continue for many weeks to months at a regular dose interval of 10 days. While we have secured supply for our current patients, the dosing schedule will not extend beyond 7 days. We will communicate any updates to this as they occur.

The price increase will affect future orders processed from and including Wednesday 31 May 2023. To ensure our patients continue to receive equal access to the medication as scheduled, we will not offer refills at the previous price.

During this shortage period, we are restricting new signups to maintain stock levels for existing patients. This will include patients who have cancelled their treatment and try to rejoin the programme. However, you can pause your treatment plan while the cost of the programme is increased and reactivate your plan later. If the price increase is inaccessible to you at this time, you can pause your treatment plan while the cost of the programme is increased and reactivate your plan later. Please note that this may affect your dose if you stop taking semaglutide, and you may have to retitrate up when you return.

If your order is currently processing and dispensed by the pharmacy, it will be shipped out as normal.

If your question is not answered here, please submit a request here and one of our patient support specialists will respond to you as soon as we can. There is a high volume of requests during this period, so please bear with us as we respond to every enquiry.

Unfortunately not, the programme is inclusive of health coaching and community access.

We have made the decision to suspend the refer a friend programme during this time, to support existing patients on the programme. We will explore reactivating this offer once supply returns to normal.

We’ve invested a lot into Juniper’s programme. The new Juniper app has a steady supply of informative video content created by our in-house team of dietitians, pharmacists, and nutritionists, which covers everything from nutrition and sleep to movement and mental health. We highly recommend downloading the free, members-only app and exploring our content catalogue (which we will continue to contribute to).

We’d also invite you to reach out to our patient support team and health coaches

You can also find us in our Slack community, where you can ask questions, share stories with other Juniper members, and maybe even meet a new friend to share the journey with.

While our medication is the foundation of our programme, it’s this support and community that leads to better weight loss outcomes.

If your order is currently processing and at the dispensing stage by the pharmacy, it will be shipped out as normal unless otherwise advised. The price modification only applies to upcoming orders, which you will be reminded of prior to being debited.

Our focus right now is on you, our existing patients. We’re not accepting new members in order to limit impacts to supply, and we have paused Juniper’s referral codes. We encourage you to make the most of Juniper’s coaching tools including dietitian support, app, and pharmacist reviews. Whilst our medication is the foundation of our programme, it’s this support that leads to better weight loss outcomes than just using medication alone.

We are exploring setting up an email waitlist for the programme and prescriber consultations, however this is currently not available.